HAEMATO AG
ISIN: DE000A289VV1
WKN: A289VV
16 November 2023 08:21AM

EQS-News: HAEMATO AG publishes figures for the third quarter of 2023: Sales increase of around 13% compared to the same period of the previous year, strong increase in EBIT margin and significant increase in

HAEMATO AG · ISIN: DE000A289VV1 · EQS - Company News
Country: Germany · Primary market: Germany · EQS NID: 1774705

EQS-News: HAEMATO AG / Key word(s): Quarter Results/9 Month figures
HAEMATO AG publishes figures for the third quarter of 2023: Sales increase of around 13% compared to the same period of the previous year, strong increase in EBIT margin and significant increase in

16.11.2023 / 08:21 CET/CEST
The issuer is solely responsible for the content of this announcement.


HAEMATO AG publishes figures for the third quarter of 2023:

Sales increase of around 13% compared to the same period of the previous year, strong increase in EBIT margin and significant increase in operating result:           

 
  • In the first nine months of the 2023 financial year, preliminary IFRS consolidated sales rose by around 13% to EUR 212.2 million compared to the same period in 2022 (EUR 188.2 million). 
     
  • The result from ordinary activities (EBITDA) increased strongly by around 33% from EUR 7.7 million to EUR 10.2 million.      
     
  • The operating result (EBIT) even increased by over 42% to EUR 9.5 million (previous year 30/09/2022: EUR 6.7 million).   
     
  • Equity increased by EUR 1.14 million to EUR 148.3 million compared to 31 December 2022. 
     
Berlin, 16 November 2023 - HAEMATO AG (ISIN: DE000A289VV1) has impressively continued its profitable growth path and increased sales in the first nine months of the 2023 financial year by EUR 24.0 million to EUR 212.18 million compared to the same period in 2022. This represents a sales growth of 12.8%.
The result from ordinary activities (EBITDA) increased from EUR 7.7 million in the previous year to EUR 10.2 million, an increase of 32.8 %. The operating result (EBIT) increased by EUR 2.8 million from EUR 6.7 million to EUR 9.5 million. This strong increase amounts to 42.2 % and results in particular from the further expansion of the profitable "Lifestyle & Aesthetics" division.
Equity increased further to EUR 148.31 million as of 30 September 2023 (previous year 31 December 2022: EUR 147.17 million). At 80.3%, the equity ratio remains high and demonstrates the Group's healthy capital structure.
"We are consistently pursuing our strategy of achieving a steady improvement in our EBIT margin through targeted product management and the successful implementation of efficiency enhancement programs. As a result, the EBIT margin increased to 4.5% in the first nine months of 2023, having already reached 3.9% in the first half of 2023. The EBIT margin improved by a whole percentage point compared to the same period of the previous year (30 September 2022: 3.5%).," says Patrick Brenske, board member of HAEMATO AG.
At this year's Annual General Meeting on 18 July in Berlin, a resolution was passed to distribute a dividend of EUR 1.20 per dividend-bearing share (previous year: EUR 1.10 per share).
Due to the extremely pleasing business performance in the third quarter of 2023, the company is raising its guidance for the 2023 financial year and now expects EBIT of EUR 10 to 12 million (previously: EUR 6 to 8 million EBIT).

About HAEMATO:
HAEMATO AG was founded in 1993 and is a pharmaceutical company with a focus on the trading of high-priced specialty pharmaceutical drugs (with a therapeutic emphasis on oncology, HIV, rheumatology and other chronic diseases) as well as the development and distribution of medical products and own brands, particularly in the area of "Lifestyle & Aesthetics". HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Further information can be found at https://haemato.de.



Contact:
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70
ir@haemato.ag


16.11.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: HAEMATO AG
Lilienthalstraße 5c
12529 Schönefeld
Germany
Phone: +49 (0)30 897 30 86 70
Fax: +49 (0)30 897 30 86 79
E-mail: ir@haemato.ag
Internet: www.haemato.ag
ISIN: DE000A289VV1
WKN: A289VV
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 1774705

 
End of News EQS News Service

1774705  16.11.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1774705&application_name=news&site_id=boersengefluester_html

Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.

The most important financial data at a glance
  2018 2019 2020 2021 2022 2023 2024e
Sales1 274,12 197,84 238,33 285,04 248,14 281,51 278,00
EBITDA1,2 9,96 1,90 3,31 12,64 9,66 11,50 11,10
EBITDA-Margin3 3,63 0,96 1,39 4,43 3,89 4,09 3,99
EBIT1,4 8,50 -18,68 1,63 11,16 8,30 10,57 10,30
EBIT-Margin5 3,10 -9,44 0,68 3,92 3,35 3,76 3,71
Net Profit (Loss)1 6,28 -1,17 -4,83 6,53 8,19 7,74 7,30
Net-Margin6 2,29 -0,59 -2,03 2,29 3,30 2,75 2,63
Cashflow1,7 0,56 -2,76 14,67 14,05 19,73 -3,32 8,40
Earnings per share8 2,70 -0,50 -1,02 1,35 1,57 1,48 1,40
Dividend per share8 1,00 0,00 0,00 1,10 1,20 0,00 0,00
Quelle: boersengefluester.de and Company information
Explanation

1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de

Auditor: Harry Haseloff

All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.

INVESTOR-INFORMATION
©boersengefluester.de
Haemato
WKN ISIN Legal Type Marketcap IPO Recommendation Plus Code
A289VV DE000A289VV1 AG 55,43 Mio € 05.12.2005 - 9F4M9H86+67
* * *
PE 2025e PE 10Y-Ø BGFL-Ratio Shiller-PE PB PCF KUV
6,75 14,80 0,46 5,83 0,37 -16,70 0,20
Dividends
Dividend '2022
in €
Dividend '2023
in €
Dividend '2024e
in €
Div.-Yield '2024e
in %
1,20 0,00 0,00 0,00%
Financial calendar
Annual General Meeting Q1-figures Q2-figures Q3-figures Annual press conference
16.07.2024 23.04.2024
Performance
Distance 60-days-line Distance 200-days-line Performance YtD Performance 52 weeks IPO
Last Price (EoD)
-1,85%
10,60 €
ATH 94,40 €
-20,72% -32,05% -60,15% -58,59% +0,00%

Advertising is an important revenue channel for us. But we understand, that sometimes it becomes annoying. If you want to reduce the number of shown ADs just simply login to your useraccount and manage the settings from there. As registered user you get even more benefits.
          Qualitätsjournalismus · Made in Germany © 2024          
The news manufactory

Good luck with all your investments

Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.

Contact

Idea & concept: 3R Technologies   
boersengefluester.de GmbH Copyright © 2024 by Gereon Kruse #BGFL